Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBARK phase 3 study of tezepelumab in adults with eosinophilic COPD
2024-517458-90-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tezspire with Placebo (2 arms). Primary endpoint: Annualized rate of moderate or severe COPD exacerbations up to 76 weeks. Planned start Jun 2025; status: authorised.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-517458-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517458-90-00.